SUBSCRIBE TODAY!
Subscribing entitles a reader to complete stories on all topics released as they happen, special features, confidential documents and access to the complete, searchable story archive online back to 2004.
IP-Watch Briefs
WIPO Patent Committee Moves To Strategic Consultations
Read More >
World Health Assembly Draft Decision On NCDs
Read More >
Inside Views

Contribute your views! Submit an Inside Views idea to info [at] ip-watch [dot] ch.

We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website.

By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

1. You agree that you are fully responsible for the content that you post. You will not knowingly post content that violates the copyright, trademark, patent or other intellectual property right of any third party or which you know is under a confidentiality obligation preventing its publication and that you will request removal of the same should you discover that you have violated this provision. Likewise, you may not post content that is libelous, defamatory, obscene, abusive, that violates a third party's right to privacy, that otherwise violates any applicable local, state, national or international law, that amounts to spamming or that is otherwise inappropriate. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual preference, disability or other classification. Epithets and other language intended to intimidate or to incite violence are also prohibited. Furthermore, you may not impersonate others.

2. You understand and agree that Intellectual Property Watch is not responsible for any content posted by you or third parties. You further understand that IP Watch does not monitor the content posted. Nevertheless, IP Watch may monitor the any user-generated content as it chooses and reserves the right to remove, edit or otherwise alter content that it deems inappropriate for any reason whatever without consent nor notice. We further reserve the right, in our sole discretion, to remove a user's privilege to post content on our site. IP Watch is not in any manner endorsing the content of the discussion forums and cannot and will not vouch for its reliability or otherwise accept liability for it.

3. By submitting any contribution to IP Watch, you warrant that your contribution is your own original work and that you have the right to make it available to IP Watch for all purposes and you agree to indemnify IP Watch, its directors, employees and agents against all damages, legal fees and others expenses that may be incurred by IP Watch as a result of your breach of warranty or of these terms.

4. You further agree not to publish any personal information about yourself or anyone else (for example telephone number or home address). If you add a comment to a blog, be aware that your email address will be apparent.

5. IP Watch will not be liable for any loss including but not limited to the following (whether such losses are foreseen, known or otherwise): loss of data, loss of revenue or anticipated profit, loss of business, loss of opportunity, loss of goodwill or injury to reputation, losses suffered by third parties, any indirect, consequential or exemplary damages.

6. You understand and agree that the discussion forums are to be used only for non-commercial purposes. You may not solicit funds, promote commercial entities or otherwise engage in commercial activity in our discussion forums.

7. You acknowledge and agree that you use and/or rely on any information obtained through the discussion forums at your own risk.

8. For any content that you post, you hereby grant to IP Watch the royalty-free, irrevocable, perpetual, exclusive and fully sub-licensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such content in whole or in part, world-wide and to incorporate it in other works, in any form, media or technology now known or later developed.

9. These terms and your posts and contributions shall be governed and interpreted in accordance with the laws of Switzerland (without giving effect to conflict of laws principles thereof) and any dispute exclusively settled by the Courts of the Canton of Geneva.

Call For Transparency In The Trans-Pacific Partnership Negotiation

In this post, three US law professors explain a recent call by over 30 legal scholars for the US Trade Representative to increase transparency for the Trans-Pacific Partnership Agreement intellectual property chapter, and their response to Ambassador Kirk’s response that he is “strongly offended” by the suggestion that the negotiation is not adequately transparent already.

Change Of Year Brings Changes In IP Community
Read More >
Viacom v. YouTube: Chipping Away At The DMCA

It was a major legal battle between copyright owners and online businesses. Then, on 5 April, online businesses won. Mostly. The US appellate court ruling in Viacom International, Inc. v. YouTube, Inc. basically upheld the legal protection that a key US statute grants to online firms. However, the ruling also opened several holes in that protection. Read More >

Latest Comments
  • KITARA WALTER on WHO Director Chan Opens Annual Assembly With Optimism, Despite Economic Woes
    Congratulations upon re-election;-WHO chief.Priori... »
  • Navi Radjou on WHO Director Chan Opens Annual Assembly With Optimism, Despite Economic Woes
    Great article. Ms. Chan may want to read our book ... »
    • For IPW Subscribers
    A guide to Geneva-based public health and intellectual property organisations. Read More >
    Monthly Reporter

    The Intellectual Property Watch Monthly Reporter, published from 2004 to January 2011, is a 16-page monthly selection of the most important, updated stories and features, plus the People and News Briefs columns.

    The Intellectual Property Watch Monthly Reporter is available in an online archive on the IP-Watch website, available for IP-Watch Subscribers.

    Access the Monthly Reporter Archive >

    Indonesia considera licencias obligatorias para tres medicamentos más contra el VIH/SIDA

    Published on 28 November 2007 @ 2:12 pm

    Print This Post Print This Post

    Intellectual Property Watch

    Por Sinfah Tunsarawuth para Intellectual Property Watch
    BANGKOK – Indonesia está considerando ejercer el derecho amparado por sus leyes de producir versiones más económicas de tres medicamentos adicionales patentados contra el VIH/SIDA sin el permiso de los titulares de patentes, tras haber utilizado esta medida anteriormente para tres medicamentos similares.

    En Indonesia se necesitan tres medicamentos antirretrovíricos de segunda línea para los pacientes afectados por el VIH/SIDA, y el financiamiento actual para los tres medicamentos podría agotarse pronto, según Samsuridjal Djauzi, médico que participa en las actividades de concesión de licencias obligatorias del gobierno. Durante el tratamiento, algunos pacientes afectados por el VIH/SIDA muestran resistencia a los medicamentos de primera línea y necesitan estos medicamentos de segunda línea para estimular el sistema inmunitario, señaló.

    Los tres medicamentos en consideración son tenofovir, didanosina y lopinavir, indicó Djauzi, quien enseña ciencias médicas en la Universidad de Indonesia en Yakarta y trabaja en una clínica con pacientes afectados por el VIH/SIDA. Djauzi concedió una entrevista a Intellectual Property Watch al margen de una reunión sobre licencias obligatorias que tuvo lugar del 21 al 23 de noviembre en Bangkok. Señaló que su grupo de trabajo actualmente recolecta datos sobre los tres medicamentos a fin de presentar propuestas al Ministro de Salud, quien tomará la decisión. Tenofovir, didanosina y lopinavir son los nombres genéricos de las versiones patentadas que producen y comercializan Gilead Sciences, Bristol-Myers Squibb y Abbott Laboratories, respectivamente.

    Djauzi dijo que actualmente alrededor de 10.000 pacientes indonesios reciben tratamiento antirretrovírico de primera línea y, en general, menos del 5 por ciento de los pacientes muestran resistencia y necesitan el tratamiento antirretrovírico de segunda línea, que es más costoso.

    En la actualidad, el Fondo Mundial de lucha contra el SIDA, la tuberculosis y la malaria suministra estos medicamentos antirretrovíricos de segunda línea a Indonesia; sin embargo, Djauzi afirmó que es posible que los insumos se agoten pronto, ya que el Fondo podría decidir reducir la ayuda a este país.

    En 2004, Indonesia dictó un decreto presidencial para hacer uso de las licencias obligatorias para dos medicamentos antirretrovíricos: lamivudina y nevirapina. En marzo de 2007, se renovó el decreto y se incluyó efavirenz, otro medicamento antirretrovírico que reemplazó a la nevirapina como medicamento de primera línea.

    Indonesia usa lamivudina, efavirenz y zidovudina como los tres medicamentos antirretrovíricos de primera línea para los pacientes indonesios con VIH/SIDA. El país no impuso una licencia obligatoria para la zidovudina, ya que la patente de dicho medicamento había vencido previamente. PT Kimia Farma, una empresa farmacéutica estatal, produce los tres medicamentos en el país.

    Djauzi señaló que si se conceden licencias obligatorias para los tres medicamentos antirretrovíricos de segunda línea, es posible que Indonesia deba importar los ingredientes de India, pero produciría las versiones genéricas localmente.

    Además afirmó que los precios de estos medicamentos antirretrovíricos de segunda línea han disminuido desde que la industria local comenzó a producir las versiones genéricas de los medicamentos de primera línea, pero advirtió que es incierto que las empresas farmacéuticas multinacionales mantengan los precios bajos sin la presión de posibles licencias obligatorias y la competencia de los medicamentos genéricos.

    “Es posible que bajen los precios ahora, pero ¿hasta cuándo?”, dijo el médico indonesio. “Sin embargo, la sociedad desea obtener un suministro sostenible de medicamentos antirretrovíricos a precios asequibles. Por lo tanto, la opción de producirlos en nuestro país es muy conveniente”.

    Djauzi afirmó en el documento presentado en la reunión de Bangkok que si bien se estima que la cantidad de indonesios afectados por el VIH/SIDA fue de 190.000 a 210.000 en 2006, los pacientes que reciben tratamiento antirretrovírico actualmente sólo ascienden a 10.000 y posiblemente el número aumente a 30.000 a fines de 2008. Posteriormente en la entrevista señaló que sin un programa de control efectivo, el número de pacientes afectados por el VIH/SIDA en Indonesia probablemente alcance el millón en 2010.

    “A largo plazo, la versión genérica de los medicamentos patentados se utilizará ampliamente en los países en desarrollo”, afirmó.

    Categories: Biodiversity/Genetic Resources/Biotech, Developing Country Policy, Español, Human Rights, Patent Policy, Public Health, Technical Cooperation/ Technology Transfer

     

    Attribution-Noncommercial-No Derivative Works 3.0 Unported 

    You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.


    Leave a Reply

    We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website. By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

    We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website.

    By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

    1. You agree that you are fully responsible for the content that you post. You will not knowingly post content that violates the copyright, trademark, patent or other intellectual property right of any third party or which you know is under a confidentiality obligation preventing its publication and that you will request removal of the same should you discover that you have violated this provision. Likewise, you may not post content that is libelous, defamatory, obscene, abusive, that violates a third party's right to privacy, that otherwise violates any applicable local, state, national or international law, that amounts to spamming or that is otherwise inappropriate. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual preference, disability or other classification. Epithets and other language intended to intimidate or to incite violence are also prohibited. Furthermore, you may not impersonate others.

    2. You understand and agree that Intellectual Property Watch is not responsible for any content posted by you or third parties. You further understand that IP Watch does not monitor the content posted. Nevertheless, IP Watch may monitor the any user-generated content as it chooses and reserves the right to remove, edit or otherwise alter content that it deems inappropriate for any reason whatever without consent nor notice. We further reserve the right, in our sole discretion, to remove a user's privilege to post content on our site. IP Watch is not in any manner endorsing the content of the discussion forums and cannot and will not vouch for its reliability or otherwise accept liability for it.

    3. By submitting any contribution to IP Watch, you warrant that your contribution is your own original work and that you have the right to make it available to IP Watch for all purposes and you agree to indemnify IP Watch, its directors, employees and agents against all damages, legal fees and others expenses that may be incurred by IP Watch as a result of your breach of warranty or of these terms.

    4. You further agree not to publish any personal information about yourself or anyone else (for example telephone number or home address). If you add a comment to a blog, be aware that your email address will be apparent.

    5. IP Watch will not be liable for any loss including but not limited to the following (whether such losses are foreseen, known or otherwise): loss of data, loss of revenue or anticipated profit, loss of business, loss of opportunity, loss of goodwill or injury to reputation, losses suffered by third parties, any indirect, consequential or exemplary damages.

    6. You understand and agree that the discussion forums are to be used only for non-commercial purposes. You may not solicit funds, promote commercial entities or otherwise engage in commercial activity in our discussion forums.

    7. You acknowledge and agree that you use and/or rely on any information obtained through the discussion forums at your own risk.

    8. For any content that you post, you hereby grant to IP Watch the royalty-free, irrevocable, perpetual, exclusive and fully sub-licensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such content in whole or in part, world-wide and to incorporate it in other works, in any form, media or technology now known or later developed.

    9. These terms and your posts and contributions shall be governed and interpreted in accordance with the laws of Switzerland (without giving effect to conflict of laws principles thereof) and any dispute exclusively settled by the Courts of the Canton of Geneva.